Passa al contenuto
Merck
  • Overexpression of angiotensin-converting enzyme 2 attenuates tonically active glutamatergic input to the rostral ventrolateral medulla in hypertensive rats.

Overexpression of angiotensin-converting enzyme 2 attenuates tonically active glutamatergic input to the rostral ventrolateral medulla in hypertensive rats.

American journal of physiology. Heart and circulatory physiology (2014-05-20)
Yang-Kai Wang, Du Shen, Qiang Hao, Qiang Yu, Zhao-Tang Wu, Yu Deng, Yan-Fang Chen, Wen-Jun Yuan, Qi-Kuan Hu, Ding-Feng Su, Wei-Zhong Wang
ABSTRACT

The rostral ventrolateral medulla (RVLM) plays a key role in cardiovascular regulation. It has been reported that tonically active glutamatergic input to the RVLM is increased in hypertensive rats, whereas angiotensin-converting enzyme 2 (ACE2) in the brain has been suggested to be beneficial to hypertension. This study was designed to determine the effect of ACE2 gene transfer into the RVLM on tonically active glutamatergic input in spontaneously hypertensive rats (SHRs). Lentiviral particles containing enhanced green fluorescent protein (lenti-GFP) or ACE2 (lenti-ACE2) were injected bilaterally into the RVLM. Both protein expression and activity of ACE2 in the RVLM were increased in SHRs after overexpression of ACE2. A significant reduction in blood pressure and heart rate in SHRs was observed 6 wk after lenti-ACE2 injected into the RVLM. The concentration of glutamate in microdialysis fluid from the RVLM was significantly reduced by an average of 61% in SHRs with lenti-ACE2 compared with lenti-GFP. ACE2 overexpression significantly attenuated the decrease in blood pressure and renal sympathetic nerve activity evoked by bilateral injection of the glutamate receptor antagonist kynurenic acid (2.7 nmol in 100 nl) into the RVLM in SHRs. Therefore, we suggest that ACE2 overexpression in the RVLM attenuates the enhanced tonically active glutamatergic input in SHRs, which may be an important mechanism underlying the beneficial effect of central ACE2 to hypertension.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Acido L-glutammico, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Kynurenic acid, ≥98%
Sigma-Aldrich
Acido L-glutammico, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-100.5%
Sigma-Aldrich
Anti-α-tubulina monoclonale, clone B-5-1-2, purified from hybridoma cell culture
Sigma-Aldrich
(−)-Norepinephrine, ≥98%, crystalline
Sigma-Aldrich
(±)-Norepinephrine (+)-bitartrate salt
Sigma-Aldrich
DL-Norepinephrine hydrochloride, crystalline, ≥97% (TLC)
Sigma-Aldrich
Acido L-glutammico, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
D-Glutamic acid, ≥99% (TLC)
Supelco
Acido L-glutammico, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Norepinephrine hydrochloride, ≥98.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
Acido L-glutammico, FCC
Sigma-Aldrich
L-Glutamic acid hydrochloride, ≥99% (HPLC)
Acido L-glutammico, European Pharmacopoeia (EP) Reference Standard
Supelco
Acido L-glutammico, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Anti-ACE2 antibody produced in rabbit, affinity isolated antibody